DILAFOR
Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications. The company’s primary goal is to decrease the incidence of slow progress of labor both after induction of labor and after spontaneous onset of labor.
DILAFOR
Industry:
Biopharma Pharmaceutical
Founded:
2003-01-01
Address:
Solna, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.dilafor.com
Total Employee:
11+
Status:
Active
Contact:
+46 70 790 02 07
Total Funding:
51 M SEK
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Euro Microsoft Exchange Online Microsoft Azure DNS Fonts.com
Similar Organizations
Current Employees Featured
Per-Olov Eriksson Co-Founder & Head of Manufacturing @ Dilafor
Co-Founder & Head of Manufacturing
Kjell Gunnarsson Co-Founder & Head of Non-Clinical Safety ,Toxicology @ Dilafor
Co-Founder & Head of Non-Clinical Safety ,Toxicology
Erik Holmer Co-Founder & Head of R&D @ Dilafor
Co-Founder & Head of R&D
Lena Degling Wikingsson CEO @ Dilafor
CEO
2011-02-01
Founder
Investors List
Praktikerinvest
Praktikerinvest investment in Venture Round - Dilafor
Rosetta Capital
Rosetta Capital investment in Venture Round - Dilafor
Ostersjöstiftelsen
Ostersjöstiftelsen investment in Venture Round - Dilafor
Official Site Inspections
http://www.dilafor.com
- Host name: dedserv4081.levonline.com
- IP address: 217.70.37.81
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Dilafor"
Dilafor AB
Healthier labor for healthier lives Dilafor is dedicated to the development of pharmaceutical products aimed at minimizing the risk for maternal and fetal complications associated with labor.See details»
Our company - Dilafor AB
Dilafor AB is a women’s health company based in Stockholm, Sweden, developing new therapies for women’s health indications with large unmet medical needs. The company was founded in 2003 by scientists from …See details»
Dilafor - Crunchbase Company Profile & Funding
Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.See details»
Dilafor - Funding, Financials, Valuation & Investors - Crunchbase
Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.See details»
Dilafor AB Company Profile | Solna, Stockholm, Sweden
Find company research, competitor information, contact details & financial data for Dilafor AB of Solna, Stockholm. Get the latest business insights from Dun & Bradstreet.See details»
Dilafor - Overview, News & Competitors | ZoomInfo.com
Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications. The company's primary goal is to decrease the incidence of dystocia …See details»
Dilafor AB - Solna, Sweden - bionity.com
Established in 2003, Dilafor AB is a Swedish R&D company focused on developing pharmaceutical products from heparin derivatives with low anticoagulant activity. The company …See details»
Dilafor AB - VentureRadar
Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications. The company’s primary goal is to decrease the incidence of slow …See details»
Our Vision - Dilafor AB
Dilafor believes that healthier labor contributes to healthier lives for mothers, children and families. Dilafor is dedicated to the development of pharmaceutical products aimed at minimizing the …See details»
Dilafor 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Dilafor. Use the PitchBook Platform to explore the full profile.See details»
Dilafor | Karolinska Development
Dilafor AB is a women’s health company based in Stockholm, Sweden, developing tafoxiparin for obstetric indications, with particular reference to protracted labor and associated …See details»
Dilafor - Crunchbase
Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.See details»
Dilafor Company Profile - Office Locations, Competitors ... - Craft
Dilafor $5.97 m in total funding,. See insights on Dilafor including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Dilafor - Contacts, Employees, Board Members, Advisors & Alumni
Dilafor AB is a Swedish drug development company focusing on the development of tafoxiparin for obstetric indications.See details»
Dilafor AB - Drug pipelines, Patents, Clinical trials - Synapse
Explore Dilafor AB with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 2 news, Disease Domain:Hemic and Lymphatic Diseases, Infectious Diseases, Technology …See details»
Karolinska Development’s portfolio company Dilafor advances …
Jan 30, 2025 Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the U.S. Food …See details»
How it works - Dilafor AB
As many as 30-50% of all term pregnant women experience planned start of labor, which carries a high risk of complications for both mothers and infants. Dilafors preclinical studies show for the …See details»
Medical need and indication - Dilafor AB
The clinical challenge and medical need Initiation of labor is one of the most frequently performed obstetric procedures in the world to prevent adverse perinatal and maternal outcome, and the …See details»
Karolinska Development’s portfolio company Dilafor recruits
Oct 27, 2021 Dilafor has now enrolled the first patient in a Phase 2a pilot study that will investigate whether treatment with subcutaneously administered tafoxiparin can improve the …See details»
Research & Development - Dilafor AB
Clinical studies Dilafor successfully completed a phase IIb clinical study on the indication Priming of labor. Reported in February 2023. The study was a multi-center, double blind, placebo …See details»